Fig. 2: Documentation on ILC in clinical drug trials per drug category.
From: Reporting on invasive lobular breast cancer in clinical trials: a systematic review
The number of manuscripts with documentation (Yes) vs. without documentation (No) on ILC are demonstrated per drug category. ADC: antibody drug conjugate; ICI: immune checkpoint inhibitors; SERD: selective estrogen receptor degrader; TKI: tyrosine kinase inhibitor.
